Horizon Therapeutics has today opened its new global headquarters in Dublin and announced the creation of up to 100 jobs in Dublin and Waterford over the next 18 months.

Horizon focuses on the discovery, development and commercialisation of medicines that address critical needs for people impacted by rare, autoimmune and severe inflammatory diseases.

The company's new 62,000 square foot facility is located at 70 St Stephen's Green in Dublin city centre.

Horizon's global headquarters have been in Dublin since 2014 and it now employs about 200 people in Ireland across a variety of key functions including finance, legal, technical operations and research and development.

The company last year bought a 44,000 square foot manufacturing facility in Waterford to support the growth of its on-market rare disease medicines and pipeline biologics.

Timothy P Walbert, Horizon's chairman, president and chief executive officer said that Ireland has been a wonderful location for Horizon for nearly 10 years.

"As a company we benefit enormously from the rich pool of talented and enthusiastic employees here," Mr Walbert said.

"Ireland is a key part of our global strategy and we will continue to invest significantly here to enhance our business and to demonstrate our support for the wider community," he added.

Taoiseach Micheál Martin said he welcomed the company's commitment to creating an additional 100 new jobs in Dublin and Waterford.

"The company's decision to add a manufacturing facility in Waterford last year further underlines the leading role Ireland plays in the company's operations. Horizon's drive and commitment to innovation and its highly skilled and talented workforce here will continue to bring the company considerable further success in the years ahead," the Taoiseach added.

Martin Shanahan, CEO of IDA Ireland, said that Horizon is one of the next generation of high growth biotech companies and its investment and job creation in both its Dublin Global HQ and its advanced manufacturing facility in Waterford is very welcome and adds to Ireland’s growing biopharma industry.